In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health

NEW YORK – Myriad Genetics said this week it will start receiving reimbursement in Japan for its BRACAnalysis Diagnostics System as a companion test to identify which metastatic pancreatic or metastatic castration-resistant prostate cancer patients harbor germline BRCA1/2 mutations and are likely to benefit from the PARP inhibitor olaparib (AstraZeneca/MSD's Lynparza). Following the test's approval in these settings by Japan's Ministry of Health, Labor, and Welfare in October, the government will now reimburse the test.